Premium
A Pilot Study of Hydroxyurea in Hormone “Escaped” Metastatic Carcinoma of the Prostate
Author(s) -
MUNDY A. R.
Publication year - 1982
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1982.tb13505.x
Subject(s) - medicine , prostate carcinoma , hormone , oncology , prostate , hormonal therapy , metastatic carcinoma , carcinoma , prostate cancer , cancer
Summary— Twenty‐two patients with metastatic carcinoma of the prostate no longer responsive to hormonal therapy with stilboestrol 1 mg tds have been studied in a Phase II clinical trial of hydroxyurea 80 mg/kg body weight every third day after discontinuing their hormonal therapy. There was a partial objective response in 22.7%, a stable state response in 1 3.6% and a subjective response in a further 31.8%. The patients who showed a response to treatment survived longer than those who did not show a response and with a better quality of life. The response rate was higher in patients who started treatment without significant delay after diagnosis of relapse. Metastatic disease responded better than the primary tumour. Side effects were not a significant problem.